A candidate live attenuated vaccine strain was constructed for West Nile virus (WN), a neurotropic flavivirus that has recently emerged in the U.S. Considerable attenuation for mice was achieved by chimerization with dengue virus type 4 (DEN4). The genes for the structural premembrane and envelope proteins of DEN4 present in an infectious cDNA clone were replaced by the corresponding genes of WN strain NY99. Two of 18 cDNA clones of a WN͞DEN4 chimera yielded full-length RNA transcripts that were infectious when transfected into susceptible cells. The two infectious clones shared a motif in the transmembrane signal domain located immediately downstream of the NS2B-NS3 protease cleavage site that separates the DEN4 capsid protein and the WN premembrane protein of the chimera. This motif, Asp and Thr at a position 3 and 6 amino acids downstream of the cleavage site, respectively, was not present in the 16 noninfectious cDNA clones. The WN͞DEN4 chimera was highly attenuated in mice compared with its WN parent; the chimera was at least 28,500 times less neurovirulent in suckling mice inoculated intracerebrally and at least 10,000 times less virulent in adult mice inoculated intraperitoneally. Nonetheless, the WN͞DEN4 chimera and a deletion mutant derived from it were immunogenic and provided complete protection against lethal WN challenge. These observations provide the basis for pursuing the development of a live attenuated WN vaccine.
W
est Nile virus (WN) belongs to the family Flaviviridae that comprises more than 60 viruses, many of which are important human pathogens. WN is a member of the Japanese encephalitis virus (JE) serocomplex of mosquito-borne flaviviruses that includes St. Louis encephalitis, JE, and Murray Valley encephalitis viruses (1, 2) . Like other members of the JE antigenic complex, WN is maintained in a natural cycle that involves mosquito vectors and birds, whereas humans are usually an incidental host. For many years, WN has been recognized as one of the most widely distributed flaviviruses with a geographic range including Africa, Australia, Europe, the Middle East, and West Asia (2, 3) . During 1999, WN first established itself in the U.S. in the northeast and mid-Atlantic states, and more recently, this virus extended its range to include the southeastern states (4, 5) . In endemic regions, most human WN infections are asymptomatic or cause mild illness with symptoms of low-grade fever, headache, body aches, rash, myalgia, and polyarthropathy. However, human epidemics with severe disease have been reported in Israel, France, Romania, and Russia. In acute severe illness, the virus can cause hepatitis, meningitis, and encephalitis, leading to paralysis and coma, resulting in death. The neuropathologic lesions are similar to those of JE, with diffuse central nervous system inflammation and neuronal degeneration. The virus is also found in the spleen, liver, lymph nodes, and lungs of infected individuals. During the 1999 outbreak of WN in the U.S., more than 60 people became ill, and seven died. Because of the recent and unexpected spread of WN from the northeast to the southeast of the U.S., this virus is considered a significant emerging disease threat that has embedded itself over a considerable region of the country. Currently, a licensed human vaccine is not available for prevention of WN disease. Mosquito control is the only practical strategy to combat the spread of disease, but effective spraying is difficult to perform in urban areas. Clearly, an effective vaccine is needed to protect at-risk populations.
Recent advances in recombinant DNA technology have allowed us to develop an approach for constructing live attenuated flavivirus vaccines (6-9). Our approach was made possible by the conservation among flaviviruses of genome organization, number of viral proteins, replicative strategy, gene expression, virion structure, and morphogenesis (10) . All flaviviruses have a positive-sense nonsegmented RNA genome that encodes a single long polyprotein processed to yield capsid (C), premembrane (preM), and envelope glycoprotein (E) structural proteins, followed by nonstructural proteins NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5, in that order. These shared properties suggested that viable chimeric viruses could be produced by replacing the genes for the viral structural proteins in a full-length infectious cDNA clone of a flavivirus with the corresponding viral genes (in cDNA form) of another flavivirus. When tested, this strategy was successful for chimeras that contained the sequence for viral structural proteins preM and E of tick-borne encephalitis virus (TBEV) or tick-borne Langat virus (LGT), whereas all other sequences were derived from the full-length infectious cDNA of mosquito-borne dengue type 4 virus (DEN4). This indicated that viral structural proteins of a disparate flavivirus, TBEV or LGT, could function in the context of cis-acting 5Ј and 3Ј sequences and nonstructural proteins of DEN4. Significantly, both chimeras proved to be highly attenuated in mice with respect to peripheral virulence, the ability of a virus to spread to the central nervous system (CNS) from a peripheral site of inoculation and cause encephalitis. Nonetheless, the chimeras proved to be immunogenic and able to induce resistance in mice against challenge with TBEV or LGT (6) (7) (8) . It appeared that a favorable balance between reduction in virus replication in vivo (attenuation) and induction of protective immunity had been achieved. We interpret this to mean that tick-borne flavivirus preM and E can interact in the context of DEN4 nonstructural proteins and cis-acting 5Ј and 3Ј sequences at a level sufficient for infectivity and induction of immunity but not sufficient for full expression of virulence that requires a high level of replication in vivo and ability to spread into the CNS.
As a logical extension of this strategy, we constructed viable WN͞DEN4 chimeras in which the structural preM and E protein genes of the distantly related mosquito-borne WN were substituted for the corresponding genes of DEN4. We also generated a WN͞DEN4 chimera with a 30-nucleotide deletion in the 3Ј noncoding region that had previously been shown to render DEN4 safe but still immunogenic in adult volunteers (11) . Studies in mice were then performed to evaluate neurovirulence, peripheral virulence, immunogenicity, and protective efficacy of the newly constructed WN͞DEN4 chimeric viruses. Chimeric WN͞DEN4 cDNA and Recovery of Infectious Virus. Plasmid p2A(XhoI) (13) containing the DEN4 full-length infectious cDNA, previously used for recovery of chimeric TBEV͞DEN4 and LGT͞DEN4 viruses (6, 7), was used for construction of WN͞DEN4 cDNA. This was achieved by substituting cDNA of the WN preM and E protein genes for those of the corresponding DEN4 genes (Fig. 1) . The source of WN cDNA was a PCR product that included nucleotides 233 to 2758 of the WN strain NY99 genome. This was also kindly provided by R. Lanciotti. The nucleotide sequence of the structural protein genes in this PCR fragment was determined and compared with the published sequence of WN NY99 (GenBank accession no. AF196835). Three nucleotide differences (C 1893 3 U, C 2370 3 U and C 2385 3 A) were identified in the E protein sequence, none of which resulted in an amino acid substitution.
Materials and Methods
Prior experience with construction and analysis of tickborne͞DEN4 chimeras indicated that we could not predict a priori the sequence of the DEN4 C protein͞tick-borne flavivirus preM protein junction required for viability (6, 7) . For this reason, we adopted an empirical approach and tested several different C͞preM junction sequences (Fig. 1) . This was not necessary for the downstream junction, because it was located within the COOH-terminal region of WN E. Initially, three sets of C͞preM junctions were tested, but only one yielded a viable WN͞DEN4 chimera (Fig. 1) . The primers used for construction of the chimeras by PCR used oligonucleotide 5Ј-TCAAAA-CAAAAGAAAAGATCTGCAGTGACCGGAATTGCAGT-CATGATTGGC-3Ј or 5Ј-TCAAAACAAAAGAAAAGATC-TGCAGGGACCGGAATTGCAGTCATGATTGGC-3Ј or 5Ј-TCAAAACAAAAGAAAAGATCTGCAGACACCGGA-ATTGCAGTCATGATTGGC-3Ј as a forward primer and oli- Restriction enzyme-cleaved WN cDNA fragment-bearing sequence for WN premembrane (preM) and envelope glycoprotein (E) structural protein genes were inserted into DEN4 cDNA at PstI and XhoI sites, which are underlined. The second junction is located in the COOH terminus of the WN E protein between the two hydrophobic domains. The amino acid and nucleotide sequences of WN are presented in bold letters, and the nucleotide numbering system is from GenBank accession no. AF196835. Infectivity of RNA transcripts from full-length cDNA constructs was tested by transfecting simian or mosquito cells and by evaluating cell cultures for evidence of infection by immunofluorescence assay. * indicates amino acids in chimeric constructs that vary at the 3ϩ position downstream of protease cleavage site. ** , not applicable.
gonucleotide 5Ј-CCGCAAGAAACGTCATAGCAATTGAC-CTGTCACTCGAGTTGATTCCCATCCACAACAGAAGA-GC-3Ј as a reverse primer. Stable full-length WN͞DEN4 cDNA clones were identified after transformation of Escherichia coli BD 1528 with a ligation mixture that contained the PCR product and the vector, both of which were digested by PstI and XhoI ( Fig. 1 ). Sequences at the junctions between WN and DEN4 genes in each chimeric plasmid were verified.
Plasmid DNA containing full-length WN͞DEN4 cDNA was linearized with Asp 718 . In vitro RNA synthesis and transfection of cells with the RNA transcripts were performed as described previously (12) . Brief ly, RNA transcripts of full-length WN͞DEN4 constructs listed in Fig. 1 were used to transfect simian LLCMK 2 , simian Vero cells, or mosquito C6͞36 cells in the presence of LipofectAmine 2000 reagent (GIBCO͞BRL) in a BSL-3 laboratory generously provided by L. Markoff (Center for Biologics Evaluation and Research, Food and Drug Administration). Transfected cells were examined by immunofluorescence assay for the presence of WN or DEN4 proteins by using a WN-or DEN4-specific hyperimmune mouse ascitic fluid. Two infectious chimeric viruses containing group 3 junctions (Fig. 1) , namely, WN͞DEN4 clones 18 and 55, were isolated. The recovered chimeras were amplified once in simian Vero or mosquito C6͞36 cells, and viral RNA was isolated and then reverse transcribed into cDNA that was used for sequence analysis (Table 1) . In a similar manner, the sequence of the Vero cell-derived WN͞DEN4 clone 18 was determined after an additional purification by two rounds of terminal end-point dilution and amplification in Vero cells. The resulting virus suspension had a titer of 1.7 ϫ 10 6 FFU͞ml.
To introduce a deletion into the 3Ј noncoding region (NCR) of WN͞DEN4 genome, the DNA fragment between the XhoI site (nucleotide 2345 of DEN4 genome; GenBank accession no. AF326827) and the Asp 718 site at the 3Ј end of plasmid WN͞DEN4-18 DNA was replaced by the corresponding XhoIAsp 718 -fragment derived from full-length cDNA of a DEN4 mutant, clone p4⌬30 (11). This mutant had 30 nucleotides deleted from the 3Ј NCR of the genome between nucleotides 10478 and 10507. Full-length RNA generated by SP6 polymerase from 10 different plasmids was tested for infectivity by transfection of simian Vero cells. Two individual WN͞DEN4-3Ј⌬30 cDNA clones were infectious. The rescued deletion mutants, WN͞DEN4-3Ј⌬30 clones 1 and 78, were purified twice by terminal end-point dilution and amplified in Vero cells to a titer of 1.4 ϫ 10 5 and 6 ϫ 10 4 FFU͞ml, respectively. Viral RNA was isolated, and the complete sequence of the 3Ј deletion mutant genome was determined ( Table 1) .
Evaluation of Parental and Chimeric Viruses in Mice.
Neurovirulence of Vero cell culture-propagated parental WN (strain NY99), parental DEN4 (strain 814669), chimeric WN͞DEN4 (clone 18), and its deletion mutant (clone 1) was evaluated in a BSL-3 facility at the Walter Reed Army Institute of Research, an American Association of Laboratory Animal Care-accredited facility, under Institutional Animal Care and Use Committeeapproved protocol number I05-01. Three-day-old SwissWebster mice (Taconic Farms) in groups of 9-12 were inoculated by the intracerebral (IC) route with decimal dilutions ranging from 0.1 to 10 5 FFU of virus in 0.03 ml of MEM͞0.25% human serum albumin. Mice were observed for 21 days for development of fatal encephalitis. The LD 50 of each virus was determined by the method of Reed and Muench (14) . Parental and chimeric viruses were also analyzed for peripheral virulence by i.p. inoculation of 3-week-old Swiss female mice in groups of 10. Mice were inoculated with decimal dilutions of virus ranging from 0.1 to 10 5 FFU and were observed for 28 days for fatal encephalitis. Moribund mice were humanely euthanized.
Mice that survived i.p. inoculation were bled on day 28 to evaluate the WN-specific neutralizing antibody response. Serum from mice in each group was pooled, and the WN-neutralizing antibody titer of the serum pool was determined by FFU reduction assay on Vero cells as described previously (9, 12) . Briefly, a 1:10 dilution of pooled sera was prepared in MEM containing 2% FBS and then heat inactivated for 30 min at 56°C. Serial 2-fold dilutions of inactivated pooled sera were mixed with an equal volume of a virus suspension containing Ϸ50 FFU of WN. The mixture was incubated for 30 min at 37°C, and 0.4 ml was then added to duplicate wells of Vero cells in a six-well plate. After 1 h of absorption at 37°C, the inoculum was removed, and cells were overlaid with MEM containing 2% FBS, 50 g͞ml of gentamicin, 0.25 g͞ml of fungizone, and 1% tragacanth gum. Antibody titer was determined after 2 days of incubation by an immunostaining focus-forming assay (12) that used WN-specific hyperimmune mouse ascitic fluid. Neutralizing antibody titer was the highest dilution of pooled sera that reduced focus formation 50% compared with sera collected from nonimmunized mice.
The surviving mice were challenged i.p. on day 29 with 100 i.p. LD 50 (10 3 FFU) of parental WN virus and observed for fatal encephalitis for a period of 21 days. Moribund mice were humanely euthanized.
Results
Construction and Recovery of Chimeric WN͞DEN4 Viruses. We constructed 18 plasmids that contained full-length chimeric 
*Numbering of nucleotide sequence of structural protein genes derived from the sequence of WN NY99 genome (GenBank accession no. AR196835) and numbering of nucleotide sequence of nonstructural protein genes derived from the sequence of DEN4 genome (GenBank accession no. AR326825). † Plasmid DNA. ‡ Clone rescued in Vero cells.
WN͞DEN4 cDNA, which included the structural preM and E protein genes of the WN strain NY99 with all other sequences derived from DEN4. Full-length RNA generated by SP6 RNA polymerase from only two of the 18 chimeric cDNAs was infectious when transfected into mosquito C6͞36 or simian Vero cells. Evidence for virus infectivity was detected by immunofluorescence assay (IFA). In the case of the two viable chimeric viruses, 80-100% of transfected cells were infected by day 5, as indicated by IFA by using WN-specific hyperimmune mouse ascitic fluid. The two viable chimeric viruses (WN͞DEN4 clones 18 and 55) had the C͞preM intergenic junction sequence of group 3 shown in Fig. 1 . The presence of this junction was confirmed by sequence analysis of the recovered chimeras. Also, the complete genomic sequence of the two chimeras rescued from cDNA in Vero cells was determined and compared with the consensus sequence of their parental WN NY99 and DEN4 viruses as well as the nucleotide sequence of the WN͞DEN4 viral chimera insert in the plasmid DNA from which infectious RNA transcripts were derived ( Table 1) . Analysis of plasmid DNAs revealed four differences in nucleotide sequence from the consensus WN sequence determined by reverse transcription-PCR of a high-titered suspension of WN strain NY99. Three of these differences produced amino acid substitutions in preM (Ile 6 3 Thr and Ile 146 3 Val) and E (Thr 282 3 Ala). In addition, variability between (i) Glu 92 and Asp and (ii) Leu 112 and Ser was identified in the DEN4 NS3 and NS4B nonstructural proteins of the WN͞DEN4 clone 55. Also, sequence of the Vero cell-grown WN͞DEN4 clone 18 differed from its progenitor plasmid cDNA sequence in the DEN4 NS4B gene. A change U 7162 3 C that caused the substitution Leu 112 3 Ser was identified. Interestingly, a different substitution at this locus, Leu 112 3 Phe, was previously observed by Blaney et al. (15) on passage of wild-type DEN4 in Vero cells.
After our success in constructing full-length infectious WN͞DEN4 cDNAs, we constructed chimeric virus mutants with a 30-nucleotide deletion in their 3Ј noncoding region. Two mutants, WN͞DEN4-3Ј⌬30 clone 1 and clone 78, were recovered from transfected Vero cells. The complete sequence of both these clones was analyzed ( Table 1 ). The sequence of clone 78 differed from the sequence of plasmid cDNA from which its infectious RNA transcripts were derived. A change of C 7141 3 U produced an amino acid substitution Thr 105 3 Ile in the NS4B protein. The WN͞DEN4-3Ј⌬30 clone 1 also exhibited only one nucleotide difference from the plasmid cDNA sequence. This resulted in the same NS4B amino acid change (Leu 112 3 Ser) that was observed in WN͞DEN4 clone 18.
The WN͞DEN4 chimera replicated more efficiently in Vero cells than did WN͞DEN4-3Ј⌬30. The unmodified WN͞DEN4 chimera reached a titer of 10 6 FFU͞ml on day 6 in cells infected with a multiplicity of infection of 0.01; this was Ϸ10-fold higher than the titer attained by the deletion mutant by day 6. The titer of the unmodified chimera was nearly the same as that attained by parental DEN4 under the same conditions (data not shown). FFU͞ml, respectively. Both chimeric WN͞DEN4 virus and the deletion mutant WN͞DEN4-3Ј⌬30 as well as parental WN strain NY99 and DEN4 strain 814669 were evaluated in 3-day-old Swiss mice for neurovirulence by direct IC inoculation (Table 2) . Wild-type WN NY99 grown in Vero cells was highly neurovirulent with an intracerebral LD 50 of 0.35 FFU in suckling Swiss mice. Wild-type DEN4 also grown in Vero cells was less neurovirulent with an IC LD 50 of 407 FFU. Both WN͞DEN4 and WN͞DEN4-3Ј⌬30 chimeric viruses exhibited a significant reduction in neurovirulence compared with their WN and DEN4 parents. All of the mice inoculated IC with 10 3 FFU of WN͞DEN4 or its 3Ј deletion mutant survived during a 21-day observation period. At a higher dose of 10 4 FFU, only 4 of 11 mice inoculated with WN͞DEN4 died. Thus, in suckling mice the WN͞DEN4 chimera was more than 28,571 times less neurovirulent than its WN parent. The chimera with the 30-nucleotide deletion was also significantly less neurovirulent than its WN parent. These observations are consistent with earlier observations that chimerization of TBEV or LGT with DEN4 significantly reduced their neurovirulence for mice (6, 7, 16) .
Peripheral Virulence in Mice. Subsequently, we evaluated the chimeric viruses for peripheral virulence, i.e., the ability of virus inoculated by the i.p. route to spread from a peripheral site to the central nervous system and cause encephalitis. Both chimeras were highly attenuated compared with their WN parent (Tables 2 and 3) . Notably, i.p. inoculation of 10 4 FFU of the deletion mutant chimera or 10 5 FFU of the unmodified chimera did not induce fatal encephalitis in 3-week-old Swiss mice, whereas the i.p. LD 50 for the WN parent was 10 FFU.
Immunogenicity and Protective Efficacy of Chimeric Viruses in Mice.
The two chimeras were immunogenic; a single i.p. inoculation of 10 2 FFU of the WN͞DEN4 chimera induced a moderate level of serum WN neutralizing antibodies (1:93), whereas a 10-fold higher concentration (10 3 FFU) induced a very high titer of WN neutralizing antibodies (1:1,189) . Also, 10 3 FFU of the chimeric WN͞DEN4-3Ј⌬30 deletion mutant stimulated a high level of such antibodies (1:292). i.p. challenge of the immunized mice on day 29 with 100 i.p. LD 50 (10 3 FFU) of parental WN indicated that the chimeras provided 90-100% protection against this high-dose WN challenge (Table 3 ). There was a good correlation between the titer of serum WN neutralizing antibodies that developed in response to immunization and the degree of resistance induced. All unvaccinated control mice developed signs of CNS disease 7-13 days after challenge with 100 i.p. LD 50 Ͼ10,000* 28,571ϫ Ͼ 100,000* Ͼ10,000ϫ WN͞DEN4-3Ј ⌬30 chimera (clone 1) Ͼ1,000* 2,857ϫ Ͼ 10,000* Ͼ1,000ϫ
Each decimal dilution was tested in 9 -12 mice in the group. *Highest concentration tested.
of WN, and these animals died shortly thereafter. To determine whether there was an age-related resistance of mice to WN, another group of 7-week-old mice also served as controls; they were the same age as immunized mice at time of challenge. This group of older control mice was challenged with one i.p. LD 50 , determined in 3-week-old mice. Seven of eight mice died during the 21-day observation period, indicating that age-dependent resistance of mice to WN was not a factor in the observed protective effect of immunization.
Discussion
Initially (6, 7), we demonstrated that, although preM and E proteins of distantly related tick-borne and mosquito-borne flaviviruses are highly divergent, these proteins could be interchanged without loss of virus viability. This approach has been used to create new chimeric flaviviruses (17) (18) (19) (20) (21) (22) .
Previously, we succeeded in constructing and recovering viable tick-borne͞DEN4 chimeras (6, 7, 16) . In these instances, the tick-borne flavivirus parent was TBEV, a highly virulent virus or Langat virus, a naturally attenuated tick-borne virus. Thus, the two components of these chimeras had disparate vector hosts, namely ticks and, in the case of DEN4, mosquitoes. Decreased efficiency of gene product interactions was thought to be the basis for the marked attenuation exhibited by these chimeras. Nonetheless, although highly attenuated in mice, the TBEV͞DEN4 and LGT͞DEN4 chimeras were immunogenic and provided considerable protection against their parental tick-borne flavivirus. In the present study, both virus parents of the WN͞DEN4 chimeras are transmitted by mosquitoes. However, vector preference differs, Aedes for DEN4 and Culex for WN (2, 3) .
In the present study, we constructed viable WN͞DEN4 chimeras that contained a DEN4 genome whose genes for structural preM and E proteins were replaced by the corresponding genes of WN strain NY99. Among flaviviruses, the hydrophobic domain between C and preM (''transmembrane signal domain'') varies in sequence and also in length, from 14 to 20 amino acids (23) . It acts as a signal sequence for translocation of preM protein into the endoplasmic reticulum lumen where posttranslation maturation of this protein occurs (10) . This signal peptide is flanked at its NH 2 -terminal region by the viral protease NS2B-NS3 cleavage site and at its COOHterminal region by a cellular signalase cleavage site. Three different junctions at the protease cleavage site between DEN4 C and WN preM protein were engineered in chimeric constructs (Fig. 1) . The C͞preM fusion sequence at the viral protease cleavage site (KR 2 S) in the chimeras was constructed to be similar to that of the DEN4 parent, which provides its NS2B-NS3 protease for the processing of the chimeric polyprotein. However, each of the three chimeric constructs contain a unique substitution in the transmembrane signal sequence at the third amino acid position downstream of the protease cleavage site (Fig. 1) . Thus, the transmembrane signal of the constructs is similar in length and differs in sequence only at the third amino acid position downstream of the protease cleavage site. Viable WN͞DEN4 virus was recovered only when construct number 3 ( Fig. 1 ) was used to prepare RNA transcripts for transfection. Infectious virus was recovered from two of five separate clones that encoded Asp in the 3ϩ amino acid position. And only these two clones contained a second-site mutation at the 6ϩ amino acid position downstream of the protease cleavage site that substituted Thr for Ile (Table 1) . In contrast, none of the 13 clones that encoded Gly or Val at the 3ϩ amino acid position produced infectious virus after transfection, suggesting that the transmembrane signal sequence between C and preM is a determinant of viability in the context of a WN͞DEN4 chimera. This is consistent with an earlier observation made with yellow fever virus that the transmembrane signal sequence between C and preM protein plays a role in viability and neurovirulence (24) .
The WN strain NY99 exhibited considerable virulence in Swiss mice; its IC LD 50 was Ϸ0.4 FFU for suckling mice and its i.p. LD 50 was 10 FFU for 3-week-old Swiss mice (Table 2) . Nearly the same level of neurovirulence was observed for a wild-type strain of WN isolated in Israel that was evaluated in CD-1 (ICR) of 407 FFU, and it was Ϸ20 times more virulent than its cDNA cloned virus (7) . In contrast, the WN͞DEN4 chimera and its 3Ј deletion mutant were significantly less neurovirulent than their wild-type DEN4 or WN parent. Only at a high dose of 10 4 FFU did a minority of mice die that were inoculated IC with WN͞DEN4 chimera. Also, the WN͞DEN4 chimera inoculated IC at this dose caused death of suckling mice later than did parental WN virus: 4-5 days after infection for wild-type WN compared with 9-13 days after infection for the chimera. LGT occurs after chimerization with DEN4 (6, 7, 16) .
Although highly attenuated, the WN͞DEN4 chimeras stimulated a moderate-to-high level of serum neutralizing antibodies against WN NY99 (Table 3 ). There was a strong correlation between the level of neutralizing antibodies to WN induced by immunization and resistance to subsequent lethal WN challenge. The immune response of mice inoculated with the chimeras was dose-dependent and indicated that the unmodified WN͞DEN4 chimera was slightly more immunogenic than the corresponding 3Ј deletion mutant. However, 90-100% protection against WN challenge was achieved when a single 10 3 FFU dose of WN͞DEN4 chimera or its 3Ј deletion mutant was used for immunization. A higher dose (10 4 FFU) of either chimera provided complete protection to WN challenge. Thus, the WN preM and E proteins of the chimeric viruses represent effective antigens able to induce complete protection to challenge with highly virulent WN. Our observations concerning safety, immunogenicity, and protective efficacy of the chimeric WN͞DEN4 vaccine candidates in mice provide a basis for extending our evaluation of the vaccine candidates to nonhuman primates and domestic animals, such as horses, which are at high risk.
